Cargando…

Management of Orthostatic Hypotension in Parkinson’s Disease

Orthostatic hypotension (OH) is a common non-motor feature of Parkinson’s disease that may cause unexplained falls, syncope, lightheadedness, cognitive impairment, dyspnea, fatigue, blurred vision, shoulder, neck, or low-back pain upon standing. Blood pressure (BP) measurements supine and after 3 mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanciulli, Alessandra, Leys, Fabian, Falup-Pecurariu, Cristian, Thijs, Roland, Wenning, Gregor K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592655/
https://www.ncbi.nlm.nih.gov/pubmed/32716319
http://dx.doi.org/10.3233/JPD-202036
_version_ 1783601229385957376
author Fanciulli, Alessandra
Leys, Fabian
Falup-Pecurariu, Cristian
Thijs, Roland
Wenning, Gregor K.
author_facet Fanciulli, Alessandra
Leys, Fabian
Falup-Pecurariu, Cristian
Thijs, Roland
Wenning, Gregor K.
author_sort Fanciulli, Alessandra
collection PubMed
description Orthostatic hypotension (OH) is a common non-motor feature of Parkinson’s disease that may cause unexplained falls, syncope, lightheadedness, cognitive impairment, dyspnea, fatigue, blurred vision, shoulder, neck, or low-back pain upon standing. Blood pressure (BP) measurements supine and after 3 minutes upon standing screen for OH at bedside. The medical history and cardiovascular autonomic function tests ultimately distinguish neurogenic OH, which is due to impaired sympathetic nerve activity, from non-neurogenic causes of OH, such as hypovolemia and BP lowering drugs. The correction of non-neurogenic causes and exacerbating factors, lifestyle changes and non-pharmacological measures are the cornerstone of OH treatment. If these measures fail, pharmacological interventions (sympathomimetic agents and/or fludrocortisone) should be introduced stepwise depending on the severity of symptoms. About 50% of patients with neurogenic OH also suffer from supine and nocturnal hypertension, which should be monitored for with in-office, home and 24 h-ambulatory BP measurements. Behavioral measures help prevent supine hypertension, which is eventually treated with non-pharmacological measures and bedtime administration of short-acting anti-hypertensive drugs in severe cases. If left untreated, OH impacts on activity of daily living and increases the risk of syncope and falls. Supine hypertension is asymptomatic, but often limits an effective treatment of OH, increases the risk of hypertensive emergencies and, combined with OH, facilitates end-organ damage. A timely management of both OH and supine hypertension ameliorates quality of life and prevents short and long-term complications in patients with Parkinson’s disease.
format Online
Article
Text
id pubmed-7592655
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-75926552020-10-30 Management of Orthostatic Hypotension in Parkinson’s Disease Fanciulli, Alessandra Leys, Fabian Falup-Pecurariu, Cristian Thijs, Roland Wenning, Gregor K. J Parkinsons Dis Review Orthostatic hypotension (OH) is a common non-motor feature of Parkinson’s disease that may cause unexplained falls, syncope, lightheadedness, cognitive impairment, dyspnea, fatigue, blurred vision, shoulder, neck, or low-back pain upon standing. Blood pressure (BP) measurements supine and after 3 minutes upon standing screen for OH at bedside. The medical history and cardiovascular autonomic function tests ultimately distinguish neurogenic OH, which is due to impaired sympathetic nerve activity, from non-neurogenic causes of OH, such as hypovolemia and BP lowering drugs. The correction of non-neurogenic causes and exacerbating factors, lifestyle changes and non-pharmacological measures are the cornerstone of OH treatment. If these measures fail, pharmacological interventions (sympathomimetic agents and/or fludrocortisone) should be introduced stepwise depending on the severity of symptoms. About 50% of patients with neurogenic OH also suffer from supine and nocturnal hypertension, which should be monitored for with in-office, home and 24 h-ambulatory BP measurements. Behavioral measures help prevent supine hypertension, which is eventually treated with non-pharmacological measures and bedtime administration of short-acting anti-hypertensive drugs in severe cases. If left untreated, OH impacts on activity of daily living and increases the risk of syncope and falls. Supine hypertension is asymptomatic, but often limits an effective treatment of OH, increases the risk of hypertensive emergencies and, combined with OH, facilitates end-organ damage. A timely management of both OH and supine hypertension ameliorates quality of life and prevents short and long-term complications in patients with Parkinson’s disease. IOS Press 2020-09-01 /pmc/articles/PMC7592655/ /pubmed/32716319 http://dx.doi.org/10.3233/JPD-202036 Text en © 2020 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Fanciulli, Alessandra
Leys, Fabian
Falup-Pecurariu, Cristian
Thijs, Roland
Wenning, Gregor K.
Management of Orthostatic Hypotension in Parkinson’s Disease
title Management of Orthostatic Hypotension in Parkinson’s Disease
title_full Management of Orthostatic Hypotension in Parkinson’s Disease
title_fullStr Management of Orthostatic Hypotension in Parkinson’s Disease
title_full_unstemmed Management of Orthostatic Hypotension in Parkinson’s Disease
title_short Management of Orthostatic Hypotension in Parkinson’s Disease
title_sort management of orthostatic hypotension in parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592655/
https://www.ncbi.nlm.nih.gov/pubmed/32716319
http://dx.doi.org/10.3233/JPD-202036
work_keys_str_mv AT fanciullialessandra managementoforthostatichypotensioninparkinsonsdisease
AT leysfabian managementoforthostatichypotensioninparkinsonsdisease
AT faluppecurariucristian managementoforthostatichypotensioninparkinsonsdisease
AT thijsroland managementoforthostatichypotensioninparkinsonsdisease
AT wenninggregork managementoforthostatichypotensioninparkinsonsdisease